Table 2. Clinical characteristics of 500 uveitis-affected eyes with and without cystoid macular edema.
| Total(n=500) | WITH cystoid macular edema | WITHOUT cystoid macular edema | P-valuea | |
|---|---|---|---|---|
| (n=124) | (n=376) | |||
| Age at onset (years) | <0.001b | |||
| Mean±SD (range) | 45±19 (1–90) | 52±18 (2–83) | 42±18 (1–90) | |
| 0–15, n (%) | 32 (6%) | 6 (5%) | 26 (7%) | |
| 16–24, n (%) | 33 (7%) | 2 (2%) | 31 (8%) | |
| 25–44, n (%) | 189 (38%) | 32 (26%) | 157 (42%) | |
| 45–64, n (%) | 161 (32%) | 46 (37%) | 115 (31%) | |
| ≥65, n (%) | 85 (17%) | 38 (31%) | 47 (12%) | |
| Gender | 0.460c | |||
| Female, n (%) | 278 (56%) | 74 (60%) | 204 (54%) | |
| Male, n (%) | 222 (44%) | 50 (40%) | 172 (46%) | |
| Onset of uveitis | <0.001c | |||
| Sudden, n (%) | 319 (64%) | 55 (44%) | 264 (70%) | |
| Insidious, n (%) | 181 (36%) | 69 (56%) | 112 (30%) | |
| Duration of an attack of uveitis | <0.001c | |||
| Limitedd, n (%) | 318 (64%) | 55 (44%) | 263 (70%) | |
| Persistente, n (%) | 182 (36%) | 69 (56%) | 113 (30%) | |
| Course of uveitis | <0.001c | |||
| Acutef, n (%) | 89 (18%) | 11 (9%) | 78 (21%) | |
| Recurrentg, n (%) | 237 (47%) | 45 (36%) | 192 (51%) | |
| Chronich, n (%) | 174 (35%) | 68 (55%) | 106 (28%) | |
| Type of inflammation | 0.127c | |||
| Granulomatous, n (%) | 74 (15%) | 25 (20%) | 49 (13%) | |
| Nongranulomatous, n (%) | 426 (85%) | 99 (80%) | 327 (87%) | |
| Laterality of uveitis | 0.004c | |||
| Unilateral, n (%) | 220 (44%) | 39 (31%) | 181 (48%) | |
| Bilateral, n (%) | 280 (56%) | 85 (69%) | 195 (52%) | |
| BSCVA (Snellen) | <0.001b | |||
| Mean±SD (range) | 0.60±0.35 (0–1.6) | 0.36±0.25 (0–1.35) | 0.68±0.34 (0–1.6) | |
| <0.1, n (%) | 39 (8%) | 15 (12%) | 24 (6%) | |
| 0.1–0.4, n (%) | 150 (30%) | 69 (56%) | 81 (22%) | |
| 0.5–1.0, n (%) | 293 (59%) | 39 (31%) | 254 (68%) | |
| >1.0, n (%) | 18 (4%) | 1 (1%) | 17 (4%) | |
| Etiology of uveitis | <0.001c | |||
| Infectious uveitis, n (%) | 74 (15%) | 10 (8%) | 64 (17%) | |
| Specific clinical entity, n (%) | 124 (25%) | 12 (10%) | 112 (30%) | |
| Uveitis associated with systemic disease, n (%) | 82 (16%) | 31 (25%) | 51 (13%) | |
| Idiopathic uveitis, n (%) | 220 (44%) | 71 (57%) | 149 (40%) |
Abbreviation: BSCVA, best spectacle-corrected visual acuity (Snellen).
a
Corrected for multiple testing (Benjamini–Hochberg).
b
Mann–Whitney U-test.
c
χ2-test.
d
≤3 months duration.
e
>3 months duration.
f
Episode characterized by sudden onset and limited duration.
g
Repeated episodes separated by periods of inactivity without treatment ≥3 months in duration.
h
Persistent uveitis with relapse in <3 months after discontinuing treatment.